Trial
NCT01208064
Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
—
Condition
Lung Cancer
Intervention
pazopanib hydrochloride
Why stopped
based on IDMC decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-07-12